GIP_HUMAN[22–51] peptide

GIP_HUMAN[22–51] peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-EKKEGHFSALPSLPVGSHAKVSSPQPRGPR-OH

H-Glu-Lys-Lys-Glu-Gly-His-Phe-Ser-Ala-Leu-Pro-Ser-Leu-Pro-Val-Gly-Ser-His-Ala-Lys-Val-Ser-Ser-Pro-Gln-Pro-Arg-Gly-Pro-Arg-OH

30

95.15%

C₁₄₀H₂₂₆N₄₄O₄₁

3181.55

Synthetic

Powder

GIP_HUMAN[22–51] is a potent proatherosclerotic peptide hormone which has a common precursor with glucose-dependent insulinotropic polypeptide (GIP). Chronic infusion of GIP_HUMAN[22–51] into ApoE−/− mice accelerates the development of aortic atherosclerotic lesions and it also increases the serum concentrations of many inflammatory and proatherogenic proteins, and induces IκB-α degradation and nuclear translocation of NF-κB in human vascular endothelial cells and macrophages.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Masaki et al (2021) GIP_HUMAN[22-51] is a new proatherogenic peptide identified by native plasma peptidomics. Sci Rep 11 14470 https://doi.org/10.1038/s41598-021-93862-w

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.